ESSPL Inhibitors
ESSPL inhibitors represent a chemical class specifically tailored to impede the function of ESSPL, a protein involved in critical signaling pathways within the cell. The inhibitors work by binding to specific domains of the ESSPL protein, thereby obstructing its interaction with other proteins or substrates that are essential for its activity. By doing so, these inhibitors effectively disrupt the signaling cascades that ESSPL is a part of, leading to a reduction in its functional activities. The design of ESSPL inhibitors is often predicated on the unique conformation of the ESSPL active site or allosteric sites, which allows for selective binding, ensuring minimal off-target effects on other proteins. The specificity of these inhibitors is crucial, as it allows for the precise modulation of pathways in which ESSPL plays a role, without inadvertently affecting other cellular processes. Inhibitors in this class are structurally diverse; however, they share a commonality in their ability to engage with the ESSPL protein at a molecular level, resulting in the attenuation of its activity.
The molecular action of ESSPL inhibitors is complex, involving direct interaction with the protein at key domains that are essential for its signaling function. These interactions may either cause conformational changes that reduce ESSPL's affinity for its substrates or directly block the active site, preventing catalytic activity. The efficacy of these inhibitors is found in their capacity to mimic or compete with natural substrates or regulatory molecules, thereby inhibiting the proper functioning of ESSPL. Furthermore, some ESSPL inhibitors may bind to regions of the protein that are involved in its post-translational modifications, thus altering its stability or its ability to be appropriately located within the cell. The action of these inhibitors can lead to a cascade of downstream effects, ultimately resulting in the dampening of the signaling pathways reliant on ESSPL. This precise inhibition is a testament to the sophisticated design of these compounds, which are crafted to target ESSPL with high affinity and specificity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically binds to FKBP12 and the resulting complex inhibits mTOR (mammalian target of rapamycin), a kinase that ESSPL requires for activation in the PI3K/AKT pathway. Inhibition of mTOR leads to reduced ESSPL activity as a result of decreased signaling through this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which play a crucial role in the activation of ESSPL by generating PIP3, a second messenger essential for the activation of AKT and subsequent activation of mTOR signaling. Inhibition of PI3K by LY294002 leads to decreased PIP3 levels, thereby inhibiting the activation of ESSPL. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which operates upstream of ERK in the MAPK pathway. Since ESSPL activity is modulated by the MAPK pathway's output, inhibiting MEK with PD98059 reduces ERK activation, thus leading to decreased ESSPL activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), part of the MAPK pathway. JNK influences the transcription of genes that can affect the activity of ESSPL. By inhibiting JNK, SP600125 indirectly reduces the functional activity of ESSPL by modulating gene transcription linked to its activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. The inhibition of p38 MAPK can decrease the activation of downstream transcription factors that regulate the expression of ESSPL, thus leading to its decreased functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, wortmannin prevents the formation of PIP3 and therefore impairs the activation of the AKT pathway, resulting in reduced activation of ESSPL. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which is upstream of several signaling pathways including the PI3K/AKT pathway that involves ESSPL activation. Inhibition of EGFR leads to reduced ESSPL activity by hindering upstream signaling. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
ZM336372 is a potent inhibitor of RAF kinase, which is upstream of the ERK/MAPK pathway. Inhibition of RAF leads to reduced signaling through the MAPK pathway, thus indirectly decreasing the functional activity of ESSPL. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinase activity can be required for full activation of several downstream pathways that may include ESSPL. By inhibiting Src kinases, dasatinib can lead to reduced ESSPL activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of downstream ERK1/2 in the MAPK pathway. Since ESSPL can be regulated by the MAPK pathway, inhibition with U0126 results in reduced ESSPL activity. | ||||||